Key result
Nomifensine increases average heart rate more than maprotiline without increasing cardiac arrhythmias.
Why the study?
The arrhythmogenic effects of the tetracyclic antidepressant maprotiline and the tetrahydroisoquinoline derivative nomifensine were investigated due to limited data on their cardiac safety.
Does maprotiline or nomifensine increase the incidence of cardiac arrhythmias in depressive patients?
RCT (n=40)
randomized
Does maprotiline or nomifensine increase the incidence of cardiac arrhythmias in depressive patients?
Maprotiline and nomifensine at 75 mg daily do not appear to increase arrhythmogenic activity in depressive patients, though they do increase average heart rate.
Answers are grounded in this paper and cite their sources.
Reassures on arrhythmia safety for these antidepressants in depression; confirms RCT profile while noting nomifensine’s greater heart rate effect.
In a prospective randomized study we searched for arrhythmogenic effects of the tetracyclic antidepressant, a maprotiline, and the tetrahydroisoquinoline derivative, nomifensine. Forty depressive patients from the psychiatric outpatients department were included in the study. Twenty patients in each group received maprotiline or nomifensine over three weeks in the recommended daily dosage of 75 mg. Rhythm analysis was performed before therapy, at the end of 3 weeks therapy, and 1 week after withdrawal from medication using a dual channel long-term ECG with monitoring periods of 10 h during normal daily activities. Before treatment, spontaneous incidence of all ventricular ectopics and of their complex forms was within the normal range when compared with ectopic activity of 121 "normal subjects" without detectable heart disease. No significant increase could be demonstrated during therapy with maprotiline or nomifensine, nor was any change observed 1 week after medication had been stopped. The same was true for supraventricular extrasystoles; atrial tachycardia, atrial flutter, and fibrillation were never seen. Sinoatrial (n=2) and atrioventricular block (n=1) were rare findings independent of and not affected by treatment. No bundle branch blocks were observed before, during, and after treatment. In contrast, despite the conservative dosage of both drugs, a therapy-dependent increase in average heart rate was found (p less than 0.001). This increase was significantly higher in patients receiving nomifensine than in those treated with maprotiline (p less than 0.001), suggesting a lower intrinsic anticholinergic activity of the latter compound.
No takes yet. Share an insight, caveat, or question.
Bethge et al. (1982) conducted an RCT in Depression (n=40). Maprotiline vs. Nomifensine was evaluated on Incidence of cardiac arrhythmias and average heart rate (p=<0.001). Maprotiline and nomifensine did not increase cardiac arrhythmias, but both caused an increase in average heart rate that was significantly higher with nomifensine (p<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: